IMPORTANCE Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered.
M endelian randomization studies and randomized trials of various lipid-lowering therapies have consistently demonstrated that lower levels of low-density lipoprotein cholesterol (LDL-C) may be causally associated with a lower risk of cardiovascular disease. [1] [2] [3] [4] Together, these studies suggest that lowering LDL-C levels should reduce the risk of cardiovascular events proportional to the absolute reduction in LDL-C, largely independent of the mechanism by which LDL-C is lowered. 5 The notable exception to this observation is the class of drugs known as cholesteryl ester transfer protein (CETP) inhibitors. 4 Although CETP inhibitors were originally designed to increase levels of high-density lipoprotein cholesterol (HDL-C), 6 the more potent CETP inhibitors also robustly lower levels of LDL-C. [7] [8] [9] [10] [11] However, in the ACCELERATE trial, treatment with the CETP inhibitor evacetrapib reduced LDL-C levels by 29 mg/dL (0.75 mmol/L) but did not reduce the risk of cardiovascular events. 11 This result has created uncertainty about the causal effect of LDL-C on the risk of cardiovascular disease and raises the possibility that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered.
In this study, a mendelian randomization analysis was conducted to evaluate the association between lower levels of LDL-C (and other measures of lipoprotein concentration) and the risk of cardiovascular events due to variants in the gene that encodes the target of CETP inhibitors and compare it to the association between lower LDL-C levels and the risk of cardiovascular events due to variants in the genes that encode the targets of statins, ezetimibe, and proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors to make inferences about whether the clinical benefit of lowering LDL-C might depend on how LDL-C is lowered. Because the cardiovascular outcome trials have evaluated the effect of treatment with a CETP inhibitor on the background of statin therapy, the associations of the CETP variants were evaluated both alone and in combination with variants of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene, which encodes the target of statins.
Methods

Study Design
The study consisted of 3 sequential parts as summarized in Figure 1 . First, a mendelian randomization study was conducted to measure the association between lipid changes due to a genetic score consisting of variants in the CETP gene and the risk of cardiovascular events. The magnitude of the association between the CETP genetic score and the risk of cardiovascular events was then compared with magnitude of the association between the risk of cardiovascular events and genetic scores consisting of variants in the HMGCR gene (NCBI Entrez Gene 3156, which encodes for the target of statins), the Niemann-Pick C1-Like 1 intracellular cholesterol transporter 1(NPC1L1) gene (NCBI Entrez Gene 29881, which encodes for the target of ezetimibe), and the PCSK9 gene (NCBI Entrez Gene 255738, which encodes for the target of PCSK9 inhibitors), respectively. The objective of this analysis was to make inferences about whether lower LDL-C levels due to CETP inhibition has the same causal effect on the risk of cardiovascular events as other methods of lowering LDL-C levels. 12 Second, a 2 × 2 factorial mendelian randomization study was conducted to measure the association between lipid changes due to combined exposure to the CETP and HMGCR genetic scores and the risk of cardiovascular events. The magnitude of these associations were then compared with the magnitude of the associations with the CETP score alone. The objective of this analysis was to make inferences about whether the effect of CETP inhibition on lipid changes and the risk of cardiovascular events is modified by inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase.
Third, a mendelian randomization study was conducted to measure the association between the risk of coronary heart disease and a score consisting of genetic variants associated with discordant changes in levels of LDL-C and apolipoprotein B (apoB). The magnitude of the association between this discordant variant genetic score and the risk of cardiovascular events was then compared with the magnitude of the association between a genetic score consisting of variants associated with concordant changes in levels of LDL-C and apoB and the risk of cardiovascular events, measured both per unit change in LDL-C and per unit change in apoB, respectively. The objective of this analysis was to make inferences about whether the causal effect of LDL on the risk of cardiovascular events is determined by the cholesterol mass carried by LDL particles (as measured by LDL-C level) or by the concentration of circulating LDL particles (as estimated by apoB level) and therefore to make further inferences about whether the clinical benefit of lowering LDL-C level may depend on how it is lowered. restrictions or exclusions. All racial/ethnic groups for which data were reported were included in the analysis. In each cohort or case-control study, race/ethnicity was self-identified using a study-specific fixed-category questionnaire. A description of the included studies and the genotyping platforms used in each study is provided in eTable 1 in the Supplement.
External replication and validation analyses included summary-level data from a total of up to 189 539 participants from 48 studies as part of the Coronary Artery Disease GenomeWide Replication and Meta-analysis plus the Coronary Artery Disease Genetics Consortium (CARDIOGRAMplusC4D). 14, 15 Contributing studies received ethical approval from their respective institutional review boards, and written informed consent was obtained from all participants. Analysis of the individual-participant data was approved by the Wayne State University institutional review board.
Study Outcomes
The primary outcome for the individual participant data analyses was major cardiovascular events, defined as a composite of the first occurrence of myocardial infarction, coronary revascularization, stroke, or coronary death. The primary outcome for analyses using summary-level data was coronary heart disease (CHD), as defined by the CARDIoGRAMplusC4D Consortium.
14,15
Genetic Instruments
The CETP genetic score was constructed by combining all variants within 100kb on either side of the CETP gene that were conditionally associated with HDL-C levels (the major lipid effect of CETP inhibition) at a genome-wide level of significance (P <5×10 −8 ) and that were in low linkage disequilibrium (r 2 <0.4) with all other variants included in the score, using a forward stepwise conditional regression procedure among participants free from cardiovascular disease at baseline in each study (eFigure 1 in the Supplement). The exposure allele for each variant was defined as the allele associated with higher HDL-C levels. 16 For each participant with individual data, a weighted CETP genetic score was calculated by summing the number of HDL-C-raising alleles that each participant inherited at each variant included in the score, weighted by each variant's conditional effect on HDL-C levels measured in mg/dL. For analyses involving summary-level data, genetic scores were calculated using the usual ratio of effect estimates method. Genetic scores for HMGCR, NPC1L1, and PCSK9 were constructed using a similar procedure, as previously described.
17,18
Allocation of Exposures
In individual-participant analyses, the CETP genetic score was dichotomized and used as an instrument to allocate participants into 2 approximately equal-sized groups based on whether their CETP score was either equal to or above the median or below the median (eFigure 2 in the Supplement). To evaluate dose response, participants were divided into 4 groups based on the quartile value of their CETP score.
To conduct the 2 × 2 factorial mendelian randomization analysis, participants were first allocated into 2 groups based on whether their HMGCR genetic score was equal to or above the median or below the median; participants in either of these 2 groups were then allocated into 2 further groups based on whether their CETP genetic score was equal to or above the median or below the median (eFigure 2 in the Supplement). 17, 18 To conduct the stratified analysis, participants were first divided into 2 groups based on whether their HMGCR score was equal to or above the median or below the median, and the associations of the CETP score with cardiovascular events was then evaluated as a continuous variable (without dichotomization to increase statistical power to detect effect modification) in each of these 2 groups separately. 
Analysis
Mendelian randomization study evaluating association between CETP variants, changes in lipid and lipoprotein levels, and risk of cardiovascular events
Objectives
To compare the causal effect of lower LDL-C and apoB levels on risk of cardiovascular events due to variants in genes that encode targets of CETP inhibitors, statins, ezetimibe, and PCSK9 inhibitors
Data Sources
Primary Analysis Individual-participant data from 14 cohort or case-control studies 13 (N = 102 837)
Replication Analysis Summary data from CARDIoGRAMplusC4D (n = 189 539)
Mendelian randomization study comparing the association between variants with discordant changes in LDL-C and apoB levels and risk of cardiovascular events with the association between variants with concordant changes in LDL-C and apoB levels and risk of cardiovascular events 
Statistical Analysis
For analyses involving individual-participant data, the absolute difference in mean levels of various biomarkers between groups was measured using linear regression, and the association with the risk of cardiovascular events was measured using logistic regression. All analyses were adjusted for age, sex, and the first 5 principal components of ancestry. Analyses were performed separately in each included study. Mendelian randomization estimates were then obtained by combining these summarized associations using a previously reported method that accounts for correlation between variants.
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For analyses involving summary-level data, the association between a genetic score and the risk of CHD was calculated by looking up the effect estimate of each variant included in that score on the risk of CHD as reported by the CARDIoGRAMplusC4D Consortium, dividing that effect size (and corresponding standard error) by the effect estimate of that variant on levels of HDL-C, LDL-C, or apoB (depending on the analysis) and then combining the adjusted effect estimates for all variants included in that score in an inverse-variance-weighted fixed-effects meta-analysis. Pleiotropy was assessed using MR-Egger regression. 20 To identify variants associated with discordant changes in levels of LDL-C and apoB, a genome-wide association study was conducted among 65 829 participants from 15 studies in Europe and the United Kingdom, all of whom had LDL-C and apoB measurements performed on the same nuclear magnetic resonance metabolomic platform (eTable 2 in the Supplement). 21, 22 Discordant variants were defined as being associated with LDL-C at P <5×10 −4 and with at least a 2-fold greater change in LDL-C level as compared with apoB, measured in mg/dL. The threshold of statistical significance for the association between each genetic score and all outcomes or biomarker differences was P < .05 (2-sided). All analyses were performed using STATA 14, R version 3.2.5 (R Project for Statistical Computing), or Golden Helix SNP & Variation Suite (version 8.1.4). A detailed description of the methods is provided in the Supplement.
Results
The weighted mean age of the 102 837 study participants was 59.9 years. The weighted mean level of high-density lipoprotein cholesterol (HDL-C) was 52.0 mg/dL; of LDL-C, 129.7 mg/dL (to convert lipid values to mmol/L, multiply by 0.0259); and of apoB, 101.4 mg/dL (eTable 3 in the Supplement). Study participants experienced a total of 13 821 first major cardiovascular events. The stepwise selection procedure identified 8 genetic variants conditionally associated with HDL-C level that were included in the CETP genetic score; 6 variants were included in the HMGCR genetic score as previously reported (eTables 4-7 in the Supplement). 17, 18 There were no differences in any nonlipid baseline characteristics between the groups being compared, thus demonstrating that allocation to each group appeared to be random ( Table 1) . The distribution of genetic scores for each group being compared in all analyses is presented in eTable 8 in the Supplement. Overall, as compared with participants with CETP scores below the median, participants with CETP scores equal to or above the median had lower mean CETP activity resulting in 4.62 mg/dL higher mean HDL-C level, 2.15 mg/dL lower mean LDL-C, 1.39 mg/dL lower mean apoB, and a corresponding lower risk of major cardiovascular events (odds ratio [OR], 0.964 [95% CI, 0.955-0.983]; P < .001). In dose response analyses, increasing quartiles of the CETP score were associated with a step-wise increase in mean HDL-C, step-wise decreases in mean LDL-C and apoB, and a corresponding step-wise decrease in the risk of major cardiovascular events (Figure 2A) .
In standardized analyses, the CETP score was associated with a very similar risk of major cardiovascular events per 10-mg/dL lower LDL-C level (and per 10-mg/dL lower apoB) as compared with the HMGCR, NPC1L1,andPCSK9 genetic scores ( Figure 2B and C).
In external replication analyses involving up to 62 240 participants with CHD and 127 299 control participants from the CARDIoGRAMplusC4D Consortium, the CETP score was associated with a lower risk of CHD (OR, 0.968 [95% CI, 0.956-0.981]; P < .001). This association was very similar in magnitude compared with the association between the HMGCR, NPC1L1, and PCSK9 genetic scores and the risk of CHD per unit change in LDL-C level (and per unit change in apoB) (eFigure 3intheSupplement).
In the 2 × 2 factorial analysis, compared with participants with both CETP and HMGCR scores below the median, participants in the group with both CETP and HMGCR scores equal to or above the median had additively higher mean HDL-C levels and additively lower mean LDL-C ( Table 2) . However, participants in this group had an attenuated less than additively lower change in mean apoB, with no further significant reduction in the risk of major cardiovascular events compared with participants in the group with higher HMGCR scores alone (Table 2 and Figure 3A) . A synthesis of the evidence from all published CETP inhibitor randomized trials demonstrated a similar attenuation in apoB reduction resulting in a discordance between the observed reduction in LDL-C and apoB levels when any CETP inhibitor was added to treatment with a statin, regardless of whether LDL-C was measured using the Friedewald equation or the β-quantification method (eTable 9 in the Supplement). [7] [8] [9] [10] [11] 23, 24 The observed attenuation in apoB reduction with combination therapy in these randomized trials recapitulates the genetic association with combined exposure to CETP and HMGCR variants observed in this study.
To further clarify the association of combined exposure to CETP and HMGCR variants with both lipoprotein changes and the risk of cardiovascular events, a stratified analysis was performed. Among participants with HMGCR scores below the median (analogous to CETP inhibitor monotherapy), the CETP score was associated with 4.81-mg/dL higher mean HDL-C level, 2.21-mg/dL lower mean LDL-C, a concordant 2.06-mg/dL lower mean apoB, and a corresponding lower risk of cardiovascular events (OR, 0.946 [95% CI, 0.921-0.972]; P < .001). By contrast, among participants with HMGCR scores equal to or above the median (analogous to combination therapy with a CETP inhibitor added to a statin), the CETP score was associated with a similar 4.42-mg/dL higher mean HDL-C level and 2.08-mg/dL lower mean LDL-C but with an attenuated 0.59-mg/dL lower mean apoB and no significant reduction in cardiovascular events (OR, 0.985 [95% CI, 0.959-1.012]; P = .26) ( Figure 3B ). The association with major cardiovascular events in this group was less than expected for the observed change in LDL-C level (P = .04) and instead was proportional to the attenuated change in apoB.
The genome-wide association study identified 21 independently inherited variants associated with discordant changes between levels of LDL-C and apoB similar in magnitude to that seen when CETP variants are combined with HMGCR variants (eTable 10 in the Supplement). In analyses involving up to 60 801 participants with coronary artery disease and 123 504 control participants from the CARDIoGRAMplusC4D Consortium, a genetic score consisting of these 21 variants was associated with a significantly less than expected risk of CHD per 10- 
Discussion
Genetic variants in the target of CETP inhibitors were associated with higher HDL-C levels and concordant reductions in levels of LDL-C and apoB and a corresponding lower risk of cardiovascular events that was similar in magnitude to the association between genetic variants in the target of other LDLlowering therapies and the risk of cardiovascular events per CETP activity, SMD (n = 6436)
unit change in level of LDL-C (and apoB). However, when combined with variants in the target of statins, variants in the target of CETP inhibitors were associated with discordant reductions in LDL-C and apoB level and a corresponding reduction in cardiovascular events that was proportional to the attenuated reduction in apoB but significantly less than expected per unit change in LDL-C. These mendelian randomization analyses suggest that the causal effect of CETP inhibition on the risk of cardiovascular events appears to be determined by changes in the concentration of apoB-containing lipoproteins rather than changes in LDL-C or HDL-C level. In external validation analyses, a genetic score consisting of 21 variants with similar naturally occurring discordance between changes in levels of LDL-C and apoB also was associated with the risk of cardiovascular disease proportional to change in level of apoB rather than LDL-C. Together, these findings suggest more generally that the causal effect of LDL on the risk of cardiovascular disease appears to be determined by the concentration of circulating apoBcontaining lipoprotein particles rather than by the total cholesterol mass carried by those particles (as estimated by the plasma LDL-C level).
These mendelian randomization results are consistent with the results of several previous discordant effects analyses of LDL-C and apoB, suggesting that the risk of cardiovascular disease is more closely related to apoB level than to LDL-C level. Under most circumstances, LDL-C and apoB levels are highly correlated and therefore provide similar information about cardiovascular risk. It is only when they become discordant that the differential effects of LDL-C and apoB on the risk of to mmol/L, multiply by 0.0259) as the difference in mean value for each group compared with the reference group, with 95% confidence intervals. Associations with major cardiovascular events were calculated using an inverse variance-weighted fixed-effects meta-analysis of the study-specific estimates of effect. In panel B, the study population was first divided into 2 groups based on whether the HMGCR score was below or equal to or greater than the median value. The association between the CETP score and the risk of major cardiovascular events was then estimated modeling the CETP score as a continuous variable scaled to the lipid effects in the dichotomous score analysis. There was evidence for effect modification of the HMGCR score on the association between the CETP genetic score and the risk of major cardiovascular events (P = .04). atherosclerosis can be evaluated. The results of these mendelian randomization analyses provide naturally randomized genetic evidence to support the previous discordant analysis findings that the likelihood of an apoB-containing lipoprotein particle entering into and being trapped within the subintimal space of the arterial wall is more closely related to the concentration of circulating apoB-containing lipoproteins than to the variable mass of cholesterol within them.
25-27
The results of the current mendelian randomization analyses suggest that the clinical benefit of lowering LDL-C level may be determined by the corresponding absolute reduction in concentration of apoB-containing particles. Therefore, the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered. Therapies such as statins, ezetimibe, and PCSK9 inhibitors that lower LDL-C level by reducing circulating LDL particle concentration through up-regulation of LDL receptors should reduce the risk of cardiovascular events proportionally to the absolute reduction in either LDL-C level or the concordant absolute reduction in apoB. By contrast, therapies that lower LDL-C level without proportionally reducing apoB level, for example by altering the lipid content of apoB-containing lipoproteins without necessarily decreasing the concentration of those particles, may have an attenuated benefit on cardiovascular disease risk reduction that is proportional to the change in apoB level but less than expected per unit change in LDL-C.
This finding may help to reconcile the causal effect of LDL on cardiovascular disease with the results of the ACCELERATE trial by providing a possible explanation for how treatment with evacetrapib can lower LDL-C level without reducing the risk of cardiovascular events. Adding a CETP inhibitor to a statin leads to an attenuated reduction in apoB-containing lipoproteins compared with treatment with a CETP inhibitor alone, thus resulting in a discordance between the observed changes in levels of LDL-C and apoB. In the ACCELERATE trial, treatment with evacetrapib plus a statin reduced LDL-C level by 37% compared with treatment with a statin plus placebo, but only reduced plasma apoB level by 15%, less than half the expected apoB reduction with evacetrapib monotherapy.
11 After 2 years of treatment, the corresponding 29-mg/dL absolute reduction in LDL-C would be expected to reduce the risk of major cardiovascular events by approximately 13% to 19%, which is much greater than the 5% to 8% reduction in risk that would be expected from the attenuated 12-mg/dL absolute reduction in apoB. 4, 28 This attenuated expected effect size based on the attenuated change in apoB falls well within the confidence bounds of the effect reported in the ACCELERATE trial (hazard ratio, 0.97 [95% CI, 0.85-1.10] for the composite outcome of cardiovascular death, myocardial infarction, or stroke).
11
Similarly, the recently completed and much larger 30 000 person REVEAL (Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification) trial reported that treatment with anacetrapib plus a statin significantly reduced the risk of cardiovascular events, but further details have not yet been reported. 29 This trial had a median follow-up of 4 years, which should be long enough to observe the full effect of the CETP inhibitor-induced lipoprotein changes on the risk of cardiovascular events. 28 The results of the current mendelian randomization analyses would suggest that treatment with anacetrapib plus a statin should reduce the risk of cardiovascular events proportional to the absolute change in apoB level, which may be less than the expected risk reduction per unit lower LDL-C level depending on the level of discordance between the change in LDL-C and apoB that occurs when anacetrapib is added to treatment with atorvastatin. Furthermore, the results of these mendelian randomization analyses also suggest that treatment with a CETP inhibitor as monotherapy may have the potential to effectively reduce the risk of cardiovascular events. Both genetic and therapeutic inhibition of CETP leads to quantitatively concordant changes in LDL-C and apoB levels when considered in the absence of HMG-CoA reductase inhibition. Therefore, treatment with a potent CETP inhibitor without a statin could lead to large concordant absolute reductions in both LDL-C and apoB, which could in turn lead to large relative reductions in cardiovascular events. Future cardiovascular outcomes trials evaluating CETP inhibitor therapy in statin-intolerant patients could test this hypothesis directly. .68
Analyses are based on summary data from up to 62 240 participants with coronary heart disease (CHD) and 127 299 control participants from the Coronary Artery DIsease Genome Wide Replication and Meta-analysis plus the Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) Consortium. Effect sizes are standardized per 10-mg/dL lower level of low-density lipoprotein cholesterol (LDL-C) or 10-mg/dL lower level of apolipoprotein B (apoB). MR-Egger regression estimates are presented for sensitivity analyses. Data markers indicate point estimates of effect; error bars, 95% confidence intervals.
Research Original Investigation Association of CETP Variants With Lipoprotein Levels and Cardiovascular Risk
The current mendelian randomization analyses reconcile the conflicting results between previous mendelian randomization studies and the CETP inhibitor randomized trials. Prior mendelian randomization studies have reported that some CETP variants are weakly associated with lower CETP activity, higher HDL-C level, slightly lower LDL-C, and a marginally lower risk of cardiovascular disease. 30, 31 These studies helped to establish CETP as a "genetically validated" drug target. The failure of CETP inhibitors to reduce the risk of cardiovascular events in 3 large randomized outcome trials therefore challenges the utility of using mendelian randomization studies to inform drug discovery and development programs. However, the prior mendelian randomization studies did not evaluate the combined effect of CETP and HMGCR variants and therefore could not have detected the attenuation in apoB reduction that occurs when CETP inhibition is combined with HMG-CoA inhibition. To provide relevant information to inform drug discovery and development, future mendelian randomization studies should be designed to explicitly evaluate the effect of variants in therapeutic targets the way therapies directed against those targets are likely to be used in clinical practice, including in combination with relevant required background therapy. 17, 18 This study has several limitations. First, the results of a mendelian randomization study do not establish causality. Second, mendelian randomization studies cannot evaluate the impact of acutely raising HDL-C to very high, supraphysiologic levels with a CETP inhibitor. It is possible that very high levels of HDL-C, reflected by a predominance of large, cholesterol-rich particles, may be deleterious and therefore may offset the potential clinical benefit of lowering levels of apoBcontaining lipoprotein particles with a CETP inhibitor.
Third, treatment with the combination of a CETP inhibitor and a statin has resulted in a small increase in systolic blood pressure in each of the 3 large cardiovascular outcome trials completed to date. 7, 11, 23 This increased blood pressure may have offset some of the potential benefit of the already attenuated apoB-lowering effect of combination therapy on the risk of cardiovascular events. Fourth, CETP inhibition might increase cardiovascular risk through some other as-yet unknown mechanism that counterbalances any benefit from LDL lowering. Fifth, the mechanism by which changes in LDL-C and apoB levels become discordant when CETP inhibition is combined with HMG-CoA reductase inhibition is unclear, but could be related to the redistribution of cholesterol between HDL and LDL particles. 32 Regardless of the mechanism, this effect has been observed in all randomized trials evaluating combined treatment with a CETP inhibitor and a statin and recapitulates the genetic effect observed in this study.
Conclusions
Combined exposure to variants in the genes that encode the targets of CETP inhibitors and statins was associated with discordant reductions in LDL-C and apoB levels and a corresponding risk of cardiovascular events that was proportional to the attenuated reduction in apoB but significantly less than expected per unit change in LDL-C. The clinical benefit of lowering LDL-C levels may therefore depend on the corresponding absolute reduction in apoB-containing lipoprotein particles. eMethods.
I. CETP genetic scores
Cholesteryl ester transfer protein (CETP) facilitates exchange of cholesteryl esters and triglycerides between HDL particles and atherogenic apolipoprotein B-containing lipoprotein particles in the plasma.
Pharmacological CETP inhibition leads to decreased CETP activity which blocks the transfer of cholesterol from HDL to LDL particles resulting in an increase in the cholesterol content of HDL particles and a reduction in the cholesterol content of LDL and other apoB-containing lipoprotein particles. As a result, CETP inhibition leads to an increase in plasma HDL-C and a decrease in plasma LDL-C concentration. Similarly, genetic variants that are associated with lower CETP activity are also associated with higher HDL-C and lower LDL-C.
Therefore, to create a genetic instrument that mimics the effect of a CETP inhibitor, we combined multiple independently inherited variants in the CETP gene to create a CETP genetic score. This genetic score is an instrument that reflects the combined effect of all the variants included in the score on CETP activity. 1 This CETP score should have a much larger effect on CETP activity and thus a much larger corresponding effect on CETP mediated changes in plasma HDL-C, LDL-C and apoB levels than any individual variant included in the score.
To create a common set of variants across all included studies, we imputed genotypes within a 1 KB window of the CETP gene to the 1000 Genomes Project reference panel (v3 2011) using IMPUTE (v2.2) software. 2, 3 We excluded variants that were monomorphic across all samples, severely deviated from Hardy-Weinberg equilibrium (p < 1 × 10 -6 ), did not have a call rate > 95% in each study, or had a minor allele frequency < 0.05.
To select variants for inclusion in the CETP genetic score, we used the following protocol. First, we tested the association of each variant in a linear regression model where the dependent variable was HDL-C (the major lipid effect of CETP inhibition) and independent variables were age, sex, study sample, and 5 principal components of ancestry to select the variant that was most strongly associated with HDL-C. Next, we iteratively tested the association of each remaining variant in the same linear model where the dependent variable was HDL-C and independent variables were age, sex, study sample, 5 principal components of ancestry, plus all variants selected in a previous step of the algorithm. The variant that was associated with HDL-C in this conditional analysis with the lowest p-value below a threshold of 5 × 10 -8 was added to the set of selected variants. Once a variant was included in the analysis, any other variant that was correlated with the selected variant at r2 > 0.4 was removed from the set of candidate variants. We then iteratively repeated this process until all variants were either selected, removed due to linkage disequilibrium with a selected variant, or were not strongly associated (p < 5 × 10 -8 ) with HDL-C in the conditional analysis. A schematic diagram of how the CETP genetic score was constructed is shown as eFigure 1.
We defined the exposure allele for each variant as the allele associated with higher HDL-C. To calculate the CETP genetic score for each participant, we multiplied the number of exposure alleles that a participant inherited at each variant included in the score by the conditional effect of that variant on HDL-C measured in mg/dL (conditional on all the other variants in the score) as estimated above. We then summed these values to create a weighted CETP genetic score for each participant. When calculating the weighted genetic scores, missing values for any variant were imputed as the mean expected conditional effect of that variant on HDL-C. To avoid potential bias toward the null from excessive imputation of mean values, we excluded participants who had missing values for two or more variants in any score from all analyses involving that score.
We also constructed an HMGCR genetic score using a similar protocol, as described previously.
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II. Allocation into exposure groups
Because all variants included in the genetic scores are inherited approximately randomly at the time of conception in a process sometimes referred to as Mendelian randomization, 1 and because each variant is inherited approximately independently of all other variants included in the score due to low linkage disequilibrium (by definition of the scores), the number of exposure alleles that a participant inherits in a genetic score should also be random.
We dichotomized each genetic score as having a value above or below the median score for participants in the population under study. Because the number of exposure alleles that a participant inherits in a score should be random, dichotomizing the genetic score as above and below the median can therefore be used as an instrument to randomly allocate the population under study into two approximately equal sized groups.
We chose to dichotomize the genetic scores in the primary analysis and use the dichotomized score as an instrument to randomly allocate study participants into two approximately equal sized groups for two reasons. First, randomly allocating study participants into two approximately equal sized groups would give our study the same structure as a randomized trial evaluating a CETP inhibitor. We designed our Mendelian randomization study to have the same structure as a randomized trial evaluating a CETP inhibitor (both alone and in combination with a statin) for clarity of presentation and to facilitate ease of interpretation for a clinical audience. Second, using the genetic scores to randomly allocate the population into approximately equal sized groups permitted us to directly estimate the separate and combined effect of variants that mimic the effect of CETP inhibitors and statins using a 2x2 factorial study design. 5, 6 To evaluate dose-response, we allocated participants into four groups based on the quartile value of their CETP genetic score. Because the number of exposure alleles that a person inherits in the CETP score should be random, allocation to each CETP genetic score quartile should also be random.
To conduct the 2x2 factorial analysis comparing the separate and combined effects of variants that mimic the effect of CETP inhibitors and statins, study participants were first allocated into two groups based on whether their HMGCR genetic score was above or below the median value. Subjects in either of these two groups were then allocated into two further groups based on whether their CETP genetic score was above or below the median value. Because all variants included in either score are inherited approximately randomly and approximately independently of each other due to low linkage disequilibrium; and because CETP and HMGCR genes are located on different chromosomes and therefore inherited independently of the other, this process should randomly allocate the study population into 4 approximately equal-sized groups: a group with both CETP and HMGCR scores below the median (the reference group analogous to a placebo group), a group with CETP scores above the median (analogous to treatment with a CETP inhibitor), a group with the HMGCR scores above the median (analogous to treatment with a statin), and a group with both the CETP and HMGCR scores above the median (analogous to treatment with combination of a CETP inhibitor and a statin). 4, 5 The success of the naturally random allocation scheme was assessed by comparing baseline characteristics among participants in each of the groups being compared. Continuous variables were compared using a t-test, dichotomous (and ordinal) variables were compared using a chi-square test, and non-normally distributed variables were compared using non-parametric rank tests or empirical resampling.
III. Harmonized definition of cardiovascular outcome events
As part of a larger project, we first harmonized the definition of all cardiovascular-related outcome variables in each of the 14 studies listed in eTable 1. We then re-coded individual level data for each study participant as necessary to satisfy the harmonized variable definitions to the extent possible, as described below.
In general, and where possible, we only included the outcomes of coronary heart disease death (as adjudicated by the individual studies); "definite" myocardial infarction (excluding "silent MI", "possible MI", "probable MI", "ECG-detected prior MI" and "resuscitated cardiac arrest"); coronary revascularization (defined as "angioplasty", "percutaneous coronary intervention" or "coronary artery bypass grafting"); stroke (using "ischemic stroke" only in studies that sub-divided stroke by type and specifically excluding "haemorrhagic stroke", "embolic stroke" or "unknown stroke type" when possible). We created new reconciled study outcome variables in each data set using the definitions described above.
The primary cardiovascular outcome for our study was major vascular events (MVE), defined as a composite of the first occurrence of non-fatal MI, coronary revascularization, stroke or coronary death.
We used both prevalent and incident cases of MI, coronary revascularization and stroke in the primary composite to meet the definition of "first occurrence" (understanding that all coronary deaths during follow-up were necessarily incident events) in the cohort studies. Therefore, the primary cardiovascular outcome MVE is a composite of prevalent MI, prevalent coronary revascularization or prevalent stroke;
or the first occurrence of incident non-fatal MI, incident coronary revascularization, incident stroke or coronary death.
We did not recode the "case" definition for the case-control studies. In the six (6) Myocardial Infarction Genetics (MIGEN) Consortium case-control studies, all "cases" were MI. 7 Therefore, these "cases"
satisfied the primary outcome definition for MVE and were included in the primary composite outcome.
In the Wellcome Trust Case-Control Consortium (WTCCC) study, case subjects had a history of either myocardial infarction or coronary revascularization before the age of 66 years, and a family history of coronary artery disease. 8 Of the 1,926 WTCCC "case" subjects, 1,377 had MI (71.5%) and the remaining 549 had coronary revascularization (202 PCI; 347 CABG) as the case ascertainment event. Because both "case" ascertainment events were included in the primary outcome definition of MVE, all 1,926 WTCCC CAD "cases" were included in the composite primary cardiovascular event outcome.
IV. Analytic methods
The association between each dichotomized weighted genetic score and various plasma biomarkers was evaluated using linear regression, and the association with MVE was evaluated using logistic regression (for combined prevalent and incident outcomes) or proportional hazards models (for incident events).
All analyses were adjusted for age, gender and the first five principal components of ancestry.
In the main analysis, the group with CETP scores below the median was used as the reference group. In the dose response analyses, the group with the lowest CETP quartile score was used as the reference group. In the 2x2 factorial analysis, the group with both the CETP and HMGCR score below the median was used as the reference group. In the stratified analyses, we compared the group with CETP scores above the median with the group that had CETP scores below the median (reference group) separately among participants with HMGCR scores above and below the median, respectively.
All analyses were conducted separately in each of the 14 studies listed in eTable 1. Within each study population, all analyses were conducted separately among each included ethnic group to minimize the potential for confounding by population stratification bias before being combined to produce the study specific summary estimate of effect.
A matrix of genetic correlations between variants was estimated in participants not having a previous MVE event at baseline only. The summarized genetic association estimates for each study were combined into Mendelian randomization estimates using weighted generalized linear regression accounting for the correlation between variants. If variants were uncorrelated, this method would be equivalent to combining the variant-specific causal estimates in an inverse-variance weighted metaanalysis (or combining the variants into a single genetic score variable and calculating the Mendelian randomization ratio estimate using this score). The regression model was:
where is the Mendelian randomization causal estimate, is a vector of the genetic associations (beta-coefficients) with the risk factor, is a vector of the genetic associations with the outcome, and the weighting matrix has terms = , where is the standard error of the genetic association with the outcome for the jth variant, and is the correlation between the j 1 th and j 2 th variants. The causal estimate from this weighted generalized linear regression is ( ) , and the standard error is ( ) , where T is a matrix transpose, and is the maximum of the residual standard error from the regression model and 1. This is equivalent to assuming a multiplicative random-effects model on the variant-specific causal effect estimates. By fixing to be no lower than 1, we ensure that the random-effects analysis is no more precise than a fixed-effect analysis would be. This method has been described previously and was implemented using the MendelianRandomization package in R (available for download at https://cran.rproject.org/web/packages/MendelianRandomization/). 9 When run as a fixed-effect analysis, it is equivalent to the commonly-used two-stage least squares method that requires individual-level data.
We did not adjust for the use of lipid-lowering therapy. We chose not to adjust for the use of lipidlowering therapy for three reasons. First, we recognize that the use of lipid-lowering therapy has the potential to bias our effect estimates toward the null when measuring the effect of the genetic scores on both LDL-C and the risk of cardiovascular events. We were willing to accept this potential bias toward the null to adopt the most conservative analysis strategy possible. Second, we wanted to perform the same analyses using the same methods in all 14 of the included studies to avoid introducing any potential bias. Because we did not have data on lipid-lowering therapy for participants in the casecontrol studies, we did not want to analyze the case-control and cohort studies differently by adjusting for lipid lowering therapy only in the cohort studies. Third, we were willing to accept that our point estimates of effect may be biased toward the null because estimating the precise magnitude of these point estimates of effect was not the primary goal of the study. Instead, the primary goal of the study was to compare the relative magnitude of the point estimates of effect for the CETP genetic score per unit change in HDL-C, LDL-C, ApoB and LDL particle number, respectively, alone and in combination with variants that mimic the effect of statins to make inferences about whether the clinical benefit of lowering LDL-C is influenced by how LDL-C is lowered.
V. External replication
To provide external validation, we compared the effect of lower CETP scores on the risk of CHD in up to 62,240 cases and 127,299 control subjects enrolled in the CARDIoGRAMplusC4D consortia studies. 10 As has been previously demonstrated, for a set of genetic markers with small effect size and in linkage equilibrium with each other, regression on a genetic risk score can be reconstructed from regressions on the individual polymorphisms without further access to individual-level data. 11 This is accomplished by weighting the association between each exposure allele and the risk of the outcome of interest by the effect size of the exposure allele on the modifiable exposure of interest, and then combining these weighted effect estimates to produce an overall weighted summary estimate of effect.
To calculate the effect of the CETP genetic score on the risk of CHD using the available summary data, we looked-up the association between each variant included in the CETP genetic score and the risk of coronary heart disease (CHD) as reported by the CARDIoGRAMplusC4D consortium (www.CARDIOGRAMPLUSC4D.org). 10 We adjusted the reported CHD effect size (and the corresponding standard error) by the effect of that variant on HDL-C (measured in mg/dl) as reported by the Global Lipids Genetic Consortium (GLGC) using the usual ratio of effect estimates method. 12 We then combined the adjusted effect estimates in a fixed-effects inverse-variance weighted meta-analysis to produce a CETP genetic scores that represent a summary estimate of the combined effect of the variants included in the score on the risk of CHD. To allow direct comparisons of these replication effect size estimates with the estimates from the main analysis, we scaled the effect of the summarized CETP scores on CHD by the difference in HDL-C observed between the groups with CETP scores above and below the median obtained from the individual participant data analysis.
VI. External validation
To externally validate our results, we conducted a genome-wide association study searching for variants that have naturally occurring discordance between changes in LDL-C and apoB concentration similar in magnitude to the discordance that occurs when CETP and HMGCR variants are combined. This GWAS Participants provided a research blood sample at recruitment (prior to their regular blood donation), which was fractionated into serum, plasma and buffy coat for DNA extraction.
DNA was extracted by LCG Genomics (UK) using a Kleargene method and aliquots were shipped on 96- Data from the INTERVAL study and the 14 European cohort studies listed in eTable 2 were then combined into a single GWAS. We excluded variants with a minor allele frequency < 0.01, and inadequate imputation quality (proper info < 0.4). After filtering, the effect size estimate for each variant was combined across all 15 studies in an inverse-variance weighted fixed effects meta-analysis to produce overall summary estimates of the effect of each variant on LDL-C and apoB, respectively. We then selected all variants that were associated with LDL-C at a threshold value of p < 5 x 10 -4 and had at least a 2-fold greater effect on LDL-C as compared to apoB measured in mg/dL. We filtered all variants with a r2 > 0.05 with the lead variant in each region to identify the final set of variants with naturally occurring discordant effects on LDL-C and apoB.
Next, we looked-up the association between each discordant variant and the risk of CHD as reported by the CARDIoGRAMplusC4D consortium. 10 We then adjusted the effect size for each discordant variant on CHD (and its standard error) by its effect on LDL-C (measured in 10 mg/dL increments). Specifically, we multiplied the natural logarithm of the odds ratio (and the corresponding standard error) for the association with CHD for each discordant variant by the reciprocal of its effect on LDL-C measured in units of 10 mg/dL and then combined these adjusted effect estimates in an inverse-variance weighted fixed effects meta-analysis to produce an overall summary estimate of effect for a genetic score consisting of these discordant variants on the risk of CHD per 10 mg/dl decrease in LDL-C. Similarly, we then adjusted the effect of each discordant variant on CHD (and its standard error) by its effect on apoB (measured in 10 mg/dL increments) and then combined these adjusted effect estimates in an inversevariance weighted fixed effects meta-analysis to produce an overall summary estimate of the effect of the discordant variant score on the risk of CHD per 10 mg/dl decrease in apoB.
For comparison, we selected 36 variants that were reported to be primarily associated with LDL-C at genome wide significance level in GLGC and looked up the effect of each of these variants on the risk of CHD as reported by the CARDIoGRAMplusC4D consortium. We then adjusted the effect of each LDL-C variant on CHD (and its standard error) by its effect on LDL-C (measured in 10 mg/dL increments on the same high-throughput NMR spectroscopy metabolomic platform) to produce an overall summary estimate of the effect of this 36-variant LDL-C score on the risk of CHD per 10 mg/dL lower LDL-C.
Similarly, we then adjusted the effect of each LDL-C variant on CHD (and its standard error) by its effect on apoB (measured in 10 mg/dL increments on the same high-throughput NMR spectroscopy metabolomic platform) and then combined these adjusted effect estimates in an inverse-variance weighted fixed effects meta-analysis to produce an overall summary estimate of the effect of the LDL-C score on the risk of CHD per 10 mg/dl decrease in apoB.
Finally, we compared the effects of the discordant variant genetic score and the 36-variant LDL-C genetic score on the risk of CHD per 10 mg/dL lower LDL-C, and per 10 mg/dL lower apoB, respectively, using a z-score.
In sensitivity analyses, the standardized effect estimates for each score were also calculated using linear regression analysis forced to pass through the origin (by leaving out the constant term in the regression equation) and coding the effect of each genetic variant in units of 10 mg/dl LDL-C or 10 mg/dl of ApoB,
respectively. This method provides numerically and computationally equivalent results to a metaanalysis of standardized effect estimates using the ratio of effect estimates method as described above.
We also calculated MR-Egger estimates of causal effect of either score on CHD by directionally aligning the effect of each variant on LDL-C (and apoB) and then using linear regression analysis retaining the constant term to estimate the causal effect of each score on the risk of CHD per 10 mg/dL lower LDL-C and per 10 mg/dL lower apoB, respectively (eTable 12).
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ARIC Atherosclerosis Risk in Communities Study (ARIC) 15
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession:
phs000280.v2.p1
The research reported in this article was supported by contract numbers HHSN268201100006C, values range from 0 to 1; with 0 representing complete equilibrium (no evidence for linkage disequilibrium) and 1 representing complete disequilibrium. Variants were included in the score if they had an r 2 value < 0.4 with all other variants included in the score using the conditional forward step-wise procedure described in the eMethods. eTable 6 Legend: LDL-C effect size, measured in mg/dl, was used to weight each polymorphism in the HMGCR genetic score in the external replication summarized HMGCR genetic score. For each variant, the magnitude of the exposure allele (the allele associated with higher LDL-C) association with LDL-C is given. For example, the exposure allele for variant rs12916 has a frequency of 56.9% and each copy of this exposure allele is associated with 2.3 mg/dL mg/dL lower LDL-C. This associations is highly significant (per allele effect association with LDL-C is 7.79E-78). Use of an alternative HMGCR score not including rs17238484 and with an r 2 threshold < 0.20 for all included polymorphisms returned essentially identical results for all analyses. In forward step-wise regression models using participant-level data, all polymorphisms included in the HMGCR score (including rs17238484) were confirmed to have independent effects on LDL-C. The table provides the association between the exposure allele (defined as the allele associated with lower LDL-C) and both LDL-C and apoB as estimated in the GWAS of 65,976 participants from the 15 studies listed in eTable 2. All participants had both LDL-C and apoB measured on the same NMR platform according to the same analytical protocol. For example, the G allele of variant rs629301 was associated with 4.5 mg/dL lower LDL-C and a corresponding 3.3 mg/dL lower apoB per copy of the G allele. The ratio of the effect of this allele on LDL-C to its effect on apoB is 1.35, indicating that each copy of the G allele at this variant is associated with a quantitatively concordant reduction in LDL-C as compared to apoB, measured in mg/dL. Concordance was arbitrarily defined as a ratio of change in LDL-C to change in apoB The last row shows that a one-unit change (or average per allele effect) of the LDL Score was associated with 1.452 mg/dl lower LDL-C (p=4.95x10 ), representing a 1.287-fold greater change in LDL-C as compared to apoB (a magnitude of difference in LDL-C and apoB change that is consistent with changes in LDL-C and apoB observed during treatment with a statin, PCSK9 inhibitor, ezetimibe or CETP inhibitor monotherapy). chr is chromosome; EA is effect allele; EAF is effect allele frequency; ES is effect size. MA is meta-analysis; IVW is inverse-variance weighted; sensitivity analysis performed using inverse-variance weighted fixed effects metaanalysis with Wald ratio standardized effect estimates groups. For the group with HMGCR genetic scores below the median (analogous to being allocated to a statin placebo), this analysis is analogous to comparing the effect of a CETP inhibitor with placebo. For the group with HMGCR genetic scores equal to or above the median (analogous to being allocated to a statin), this analysis is analogous to comparing the effect of a CETP inhibitor with placebo on the background of statin therapy (i.e. analogous to evaluating the effect of combination therapy with a CETP inhibitor and a statin with statin therapy alone).
